Weight & metabolism
Semaglutide
Wegovy, Ozempic
Semaglutide is a GLP-1 receptor agonist approved by the FDA for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). It is one of the most extensively studied peptide medicines.
Key facts
- Commonly discussed for: weight management and type 2 diabetes.
- Evidence (A): The STEP 1 trial alone randomized 1,961 adults and found 14.9% average weight loss at 68 weeks versus 2.4% with placebo, and it is supported by a broad phase 3 program.
- FDA status: FDA-approved. FDA approved Wegovy for chronic weight management in June 2021, and FDA reports the semaglutide shortage is resolved, ending the period when broad compounding of copies was tolerated.
- Legitimate access: Rx brand.
- Last reviewed: October 1, 2026.